GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » YoY Rev. per Sh. Growth

Enlivex Therapeutics (Enlivex Therapeutics) YoY Rev. per Sh. Growth : 0.00% (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Enlivex Therapeutics's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2023 was 0.00%.

Enlivex Therapeutics's Revenue per Share for the three months ended in Sep. 2023 was $0.00.


Enlivex Therapeutics YoY Rev. per Sh. Growth Historical Data

The historical data trend for Enlivex Therapeutics's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enlivex Therapeutics YoY Rev. per Sh. Growth Chart

Enlivex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enlivex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Enlivex Therapeutics YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Enlivex Therapeutics's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2022 )
=(Revenue per Share (A: Dec. 2022 )-Revenue per Share (A: Dec. 2021 ))/ | Revenue per Share (A: Dec. 2021 ) |
=(0-0)/ | 0 |
=N/A %

Enlivex Therapeutics's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Sep. 2023 )
=(Revenue per Share (Q: Sep. 2023 )-Revenue per Share (Q: Sep. 2022 )) / | Revenue per Share (Q: Sep. 2022 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enlivex Therapeutics YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Traded in Other Exchanges
Address
14 Einstein Street, Nes Ziona, ISR, 7403618
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics (Enlivex Therapeutics) Headlines

From GuruFocus

Enlivex Announces Upcoming May Conference Presentations

By GuruFocusNews GuruFocusNews 07-09-2022